Table 3 Major adverse cardiac events and medication therapy
Major Adverse Cardiac Events | |
All-cause mortality n, (%) | 1 (16.7%) |
Myocardial infarction n, (%) | 1 (16.7%) |
Emergent cardiac or aorta surgery n, (%) | 0 (0%) |
Selective cardiac or aorta surgery n, (%) | 0 (0%) |
Unplanned interventional therapy n, (%) | 3 (50%) |
New or worsening HF | 3 (50%) |
Erosion of device through LV | 0 (0%) |
Cardiac tamponade | 0 (0%) |
Device migration | 0 (0%) |
Device embolization | 1 (0%) |
Peripheral embolization/stroke | 0 (0%) |
Medication Therapy | |
DAPT n, (%) | 6 (100%) |
Statin n, (%) | 6 (100%) |
Warfarin n, (%) | 6 (100%) |
β-Blocker n, (%) | 6 (100%) |
ACEI/ARB n, (%) | 5 (83.3%) |
Spironolactone n, (%) | 5 (83.3%) |